Literature DB >> 22727547

Dietary energy density, inflammation and energy balance in palliative care cancer patients.

Ola Wallengren1, Ingvar Bosaeus, Kent Lundholm.   

Abstract

BACKGROUND & AIMS: Diet energy density is correlated with energy intake in patients with advanced cancer. Little information is available about the effects of energy density on energy balance, nor about the influence of other factors, such as systemic inflammation and disease stage. We assessed whether dietary energy density or energy intake predict energy balance over 4 months in patients with advanced cancer. We examined also the influence of systemic inflammation and survival time.
METHODS: Energy balance was calculated from the change in body energy content by repeated dual-energy X-ray scans in 107 patients for a total of 164 4-month measurement periods. A linear mixed model was used to investigate relationships between diet energy density (kcal/g), energy intake (kcal/day) and energy balance with systemic inflammation and survival as covariates.
RESULTS: In an unadjusted model, the energy density of solid food and energy intake were positive predictors of energy balance (P < 0.03). A 1-SD increase in energy density and energy intake increased energy balance by 38 and 41 kcal/day, respectively. The total diet energy density did not predict energy balance (P > 0.05). Survival was positively (P < 0.001), and systemic inflammation negatively (P = 0.005) associated with energy balance. Only energy intake remained a significant predictor of energy balance after adjustment for survival and inflammatory status.
CONCLUSIONS: Dietary energy density is positively associated with energy balance in patients with advanced cancer. Relations between energy intake, energy density and energy balance are affected by systemic inflammation. Thus, targeting systemic inflammation may be important in nutritional interventions in this patient group.
Copyright © 2012 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22727547     DOI: 10.1016/j.clnu.2012.05.023

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  6 in total

Review 1.  Lifestyle Medicine Interventions in Patients With Advanced Disease Receiving Palliative or Hospice Care.

Authors:  Gowri Anandarajah; Haran Asher Mennillo; Gregory Rachu; Tyler Harder; Jyotsna Ghosh
Journal:  Am J Lifestyle Med       Date:  2019-02-15

Review 2.  Key determinants of energy expenditure in cancer and implications for clinical practice.

Authors:  S A Purcell; S A Elliott; V E Baracos; Q S C Chu; C M Prado
Journal:  Eur J Clin Nutr       Date:  2016-06-08       Impact factor: 4.016

3.  Nutrient intakes associated with elevated serum C-reactive protein concentrations in normal to underweight breastfeeding women in Northern Kenya.

Authors:  Masako Fujita; Eleanor Brindle; Yun-Jia Lo; Pamela Castro; Felipe Cameroamortegui
Journal:  Am J Hum Biol       Date:  2014-08-07       Impact factor: 1.937

4.  Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients.

Authors:  Ola Wallengren; Kent Lundholm; Ingvar Bosaeus
Journal:  Support Care Cancer       Date:  2013-01-13       Impact factor: 3.603

Review 5.  Nutritional Issues in Head and Neck Cancer Patients.

Authors:  Federico Bozzetti; Paolo Cotogni
Journal:  Healthcare (Basel)       Date:  2020-04-17

6.  Diagnostic criteria for cancer cachexia: reduced food intake and inflammation predict weight loss and survival in an international, multi-cohort analysis.

Authors:  Lisa Martin; Maurizio Muscaritoli; Isabelle Bourdel-Marchasson; Catherine Kubrak; Barry Laird; Bruno Gagnon; Martin Chasen; Ioannis Gioulbasanis; Ola Wallengren; Anne C Voss; Francois Goldwasser; R Thomas Jagoe; Chris Deans; Federico Bozzetti; Florian Strasser; Lene Thoresen; Sean Kazemi; Vickie Baracos; Pierre Senesse
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-08-27       Impact factor: 12.910

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.